Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Qing Xi Ooi"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 6, Pp 758-769 (2023)
Abstract BI 730357 is investigated as an oral treatment of plaque psoriasis. We analyzed the impact of three dosage regimens on the Psoriasis Area and Severity Index (PASI) response with modeling based on phase I and II data from 109 healthy subjects
Externí odkaz:
https://doaj.org/article/9f3709a3d792455c8294af56375c3e83
Autor:
Robin J. Svensson, Qing Xi Ooi, Lena E. Friberg, Narendra Maharaj, Pramod Kumar Reddy, Luis López‐Lázaro, Emma Hansson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 2, Pp 154-167 (2023)
Abstract Dr. Reddy's Laboratories rituximab (DRL_RI; Dr. Reddy's Laboratories SA, Basel, Switzerland) is under development as a rituximab biosimilar. Study RI‐01‐002 (Clinical Trials Registry ‐ India/2012/11/003129), comparing DRL_RI to the ref
Externí odkaz:
https://doaj.org/article/d9761b2646aa411991644ebe95845175
Autor:
Yoshiko Tomita, Emma Hansson, Florent Mazuir, Gustaf J Wellhagen, Qing Xi Ooi, Enrica Mezzalana, Atsushi Kitamura, Daisuke Nemoto, Sébastien Bolze
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 4, Pp 1014-1026 (2022)
Abstract Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin usi
Externí odkaz:
https://doaj.org/article/3e3132820bcb4d2da779643ed7da92c4
Autor:
Robin J. Svensson, Qing Xi Ooi, Lena E. Friberg, Narendra Maharaj, Pramod Kumar Reddy, Luis López‐Lázaro, Emma Hansson
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 12:154-167
Dr. Reddy's Laboratories rituximab (DRL_RI; Dr. Reddy's Laboratories SA, Basel, Switzerland) is under development as a rituximab biosimilar. Study RI-01-002 (Clinical Trials Registry - India/2012/11/003129), comparing DRL_RI to the reference medicina
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology.
Autor:
Yoshiko Tomita, Emma Hansson, Florent Mazuir, Gustaf J Wellhagen, Qing Xi Ooi, Enrica Mezzalana, Atsushi Kitamura, Daisuke Nemoto, Sébastien Bolze
Publikováno v:
Clinical and translational science. 15(4)
Imeglimin is an orally administered first-in-class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population
Publikováno v:
Br J Clin Pharmacol
Publikováno v:
Clinical Pharmacokinetics. 56:1555-1566
Warfarin acts by inhibiting the reduction of vitamin K (VK) to its active form, thereby decreasing the production of VK-dependent coagulation proteins. The aim of this research is to develop a joint model for the VK-dependent clotting factors II, VII
Publikováno v:
The AAPS journal. 21(5)
Assumptions inherent to pharmacometric model development and use are not routinely acknowledged, described, or evaluated. The aim of this work is to present a framework for systematic evaluation of assumptions. To aid identification of assumptions, w
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-12 (2018)
Scientific Reports
Scientific Reports
Warfarin dosing methods based on existing models for warfarin and the international normalised ratio (INR) give biased maintenance dose predictions at the upper and lower quantiles of dose requirements. The aim of this work is to propose a conceptual